390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

Bibliographic Details
Main Authors: Thomas Davis, Jessica Price, Ammar Sukari, Roger Cohen, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items